

# **Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/E272D1F771B3EN.html>

Date: August 2022

Pages: 78

Price: US\$ 3,500.00 (Single User License)

ID: E272D1F771B3EN

## **Abstracts**

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 19 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Estrogen Receptor Beta - Drugs In Development, 2022, outlays comprehensive information on the Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo%li%or hetero-dimers that interact with specific DNA sequences to activate transcription. The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 5, 2 and 6 respectively. Similarly, the universities portfolio in

Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Women's Health, Musculoskeletal Disorders, Genetic Disorders, Hormonal Disorders, Immunology, Infectious Disease, Male Health, Metabolic Disorders and Respiratory which include indications Multiple Sclerosis, Alzheimer's Disease, Breast Cancer, Osteoporosis, Prostate Cancer, Vasomotor Symptoms of Menopause (Hot Flashes), Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Respiratory Distress Syndrome, Bile Duct Cancer (Cholangiocarcinoma), Carcinomas, Colon Cancer, Coronavirus Disease 2019 (COVID-19), Dementia, Demyelinating Diseases, Depression, Endometrial Cancer, Fallopian Tube Cancer, Hormone Sensitive Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2<sup>li</sup>Breast Cancer), Inflammation, Leiomyosarcoma, Male Hypogonadism, Malignant Pleural Mesothelioma, Neuromyelitis Optica (Devic's Syndrome), Obesity, Ovarian Cancer, Peritoneal Cancer, Post Menopausal Mood Disorder, Precocious Puberty, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.

Furthermore, this report also reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)

The report reviews Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development

ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading

companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Overview

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Avivia BV

Eagle Pharmaceuticals Inc

Eli Lilly and Co

Endece LLC

Endoceutics Inc

Estrigenix Therapeutics Inc

Helixmith Co Ltd

Karo Pharma AB

Kissei Pharmaceutical Co Ltd

MEI Pharma Inc

Vivesto AB

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Drug Profiles

acolbifene + prasterone - Drug Profile

Product Description

Mechanism Of Action

acolbifene hydrochloride - Drug Profile

Product Description

Mechanism Of Action  
AUS-131 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
dehydrodiconiferyl alcohol - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Drug to Agonize ER-Beta for Multiple Sclerosis - Drug Profile  
Product Description  
Mechanism Of Action  
EGX-358 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
erteberel - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
estradiol - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
fosfestrol - Drug Profile  
Product Description  
Mechanism Of Action  
fulvestrant - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
fulvestrant - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
KB-3944 - Drug Profile  
Product Description  
Mechanism Of Action  
KB-9520 - Drug Profile

Product Description  
Mechanism Of Action  
History of Events  
Libidua - Drug Profile  
Product Description  
Mechanism Of Action  
Loseasonique - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
NDC-1308 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Small Molecule to Agonize ESR2 for Obesity and Depression - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Small Molecule to Agonize ESR2 for Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Small Molecules to Agonize ESR2 for Multiple Sclerosis - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Small Molecules to Agonize Estrogen Beta Receptor for Inflammatory Diseases and  
Oncology - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2  
or NR3A2 or ESR2) - Dormant Products  
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2  
or NR3A2 or ESR2) - Discontinued Products  
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2  
or NR3A2 or ESR2) - Product Development Milestones  
Featured News & Press Releases  
Dec 03, 2020: AstraZeneca presents new data on fulvestrant at the 2020 San Antonio

## Breast Cancer Symposium (SABCS)

May 04, 2020: Eagle Pharmaceuticals advances novel and proprietary formulation of Fulvestrant product candidate EA-114; company to request additional meeting with U.S. Food and Drug Administration

Dec 09, 2019: Eagle Pharmaceuticals commences dosing in pilot study for novel estrogen receptor antagonist product candidate

Aug 05, 2019: Eagle Pharmaceuticals announces Clinical Development Plan of innovative product intended to deliver maximum Estrogen Receptor inhibition in patients with Estrogen Receptor (ER)-Positive Breast Cancer

Mar 27, 2019: Combo better for HR+ breast cancer patients

Oct 30, 2018: Eagle Pharmaceuticals announces results of study for fulvestrant

Oct 20, 2018: New option for women with advanced breast cancer resistant to hormone therapy

Oct 04, 2018: Mayo researchers identify potential new treatment for subset of women with triple-negative breast cancer

Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston

Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product

Dec 11, 2017: AstraZeneca's Faslodex Rejects For Use Within NHS Scotland

Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant

Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib

Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib

Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AstraZeneca Plc, 2022

Pipeline by Avivia BV, 2022

Pipeline by Eagle Pharmaceuticals Inc, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by Endece LLC, 2022

Pipeline by Endoceutics Inc, 2022

Pipeline by Estrigenix Therapeutics Inc, 2022

Pipeline by Helixmith Co Ltd, 2022

Pipeline by Karo Pharma AB, 2022

Pipeline by Kissei Pharmaceutical Co Ltd, 2022

Pipeline by MEI Pharma Inc, 2022

Pipeline by Vivesto AB, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Dormant Products, 2022 (Contd..3)

Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

## I would like to order

Product name: Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/E272D1F771B3EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E272D1F771B3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970